CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...